NanoVibronix Announces Agreement For Clinical Study Of UroShield At The University Of Michigan
Portfolio Pulse from Benzinga Newsdesk
NanoVibronix, Inc. (NASDAQ:NAOV) has entered into a Research Agreement with the University of Michigan to conduct a Randomized Control Trial study of its UroShield device. The study aims to provide clinical evidence for an FDA application for permanent clearance. The trial will focus on nursing home residents to assess the device's impact on urinary tract infections, catheter blockages, pain, and quality of life. A pilot with 20 patients will precede the full study of over 300 patients, set to begin in the first half of 2024.
November 28, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NanoVibronix's agreement with the University of Michigan for a clinical study of UroShield could positively influence its FDA clearance process. The study's outcomes may significantly impact the company's product credibility and market potential.
The clinical study is directly related to NanoVibronix's product, UroShield, and is a critical step towards obtaining permanent FDA clearance. Positive study results could lead to increased investor confidence and a higher demand for the product, likely resulting in a positive short-term impact on NAOV's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100